Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).

Latest news

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’cabozantinib franchise to $1bn in sales in 2025.
Ipsen’s liver cancer treatment clears phase III trial

Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial
Pfizer's SMO inhibitor boosts survival in blood cancer trial

Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is
Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Ipsen and Exelixis will use the findings to pursue new first-line indications in RCC, a prevalent and difficult to diagnose cancer. ... therapy. French biotech Ipsen signed and exclusive licensing agreement with Exelixis in February for the

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Accelerating innovation

Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... It currently has a second-line licence in Europe, but Ipsen
Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Exelixis appoints Andrew Peters to newly created position

Exelixis appoints Andrew Peters to newly created position. He joins the biotech as its vice president, strategy. ... California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.
Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Medical Writer - Creative and Scientific Projects: DOE

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager- 4 days per week or full-time: Salary TBC

Account Director or Senior Account Director: Salary TBC

Healthcare PR Senior Account Manager: Salary TBC

Graduate Scientific Editor: DOE

Account Manager: Negotiable

Associate Scientific Director: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer: Salary is DOE

Senior Writer, Healthcare Advertising, London: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager – Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....